Oral osteoporosis meds appear to reduce the risk of jaw degradation

BOSTON, Mass. (Jan. 2, 2008) — Athanasios Zavras began receiving messages from distraught patients in 2005 after case reports linked oral osteoporosis meds to bone death in the jaw. A number of doctors and dentists advised women and men taking these drugs to postpone dental work, fearing that procedures such as tooth extractions would exacerbate the problem. That’s when Zavras, an associate professor in the Harvard School of Dental Medicine, decided to take a closer look at the purported link.

After analyzing the medical claims of 714,217 people, Zavras, along with Vassiliki Cartsos at the Tufts University School of Dental Medicine and Shao Zhu of Ingenix—i3 Drug Safety (the company that provided medical claims data), have concluded that oral osteoporosis meds seem to reduce the risk of jaw degradation. Clinical studies are needed to replicate and clarify the results, which appear in the January issue of the Journal of the American Dental Association.

“This is good news for the roughly 3 million Americans who take Fosamax, Actonel, Boniva or similar osteoporosis meds orally,” says Zavras, who is also director of dental public health in the Department of Oral Health Policy and Epidemiology.

The drugs, which are called bisphosphonates, inhibit cells that break down bone tissue, and a growing number of Americans with osteoporosis or low bone mass ingest them orally to halt bone loss. In fact, they have been used for this purpose since 1977. Some cancer patients also rely on bisphosphonates to prevent bone fragility and metastasis, but these individuals typically receive potent intravenous versions of the drugs.

In 2003, case reports linked the potent versions to bone death in the jaw, and subsequent studies confirmed the statistical significance of the association. Concern was limited to intravenous bisphosphonates until May 2005, when the Journal of Oral and Maxillofacial Surgery published a report on 63 patients with bone death in the jaw. Seven of those patients had taken oral bisphosphonates.

Zavras and his colleagues used a medical claims database from a large national health insurance plan to probe the connection. They analyzed records coded under osteoporosis, female breast cancer, lung cancer, prostate cancer or multiple myeloma from April 2000 through April 2006, which gave them a pool of 714,217 people.

Based on pharmacy and drug infusion claims, the researchers were able to determine if these individuals had received oral bisphosphonates, intravenous bisphosphonates, or neither. Next, the team examined claims for adverse bone outcomes and major surgery in the oral cavity to determine which patients might have experienced “jaw death.”

Osteoporosis patients who took oral bisphosphonates were slightly less likely to have adverse jaw outcomes than osteoporosis patients who were not taking the drugs. The protective association was statistically significant. A generally similar pattern emerged in the analysis of people with cancer. Those who had received oral bisphosphonates experienced protective associations or slightly increased risks that were not statistically significant. But receiving intravenous bisphosphonates significantly increased an individual’s risk for adverse jaw outcomes in both cancer patients and those with osteoporosis.

“Our findings on intravenous bisphosphonates are consistent with the literature, which makes me confident that our findings on oral bisphosphonates are correct,” says Zavras. “We’re currently recruiting patients for a clinical study to confirm them.”


Source: Harvard Medical School

Related stories:

Doctors warn patients of HPV link to oral cancer
Ten years ago, most of Dr. Brian Nussenbaum's oral cancer patients were men over 60 who used tobacco and drank heavily. Today, his patients with oral cancer look different. And so does the risky behavior that seems to be leading to their cancer.
Lack of vitamin D linked to Parkinson's disease
A majority of Parkinson's disease patients had insufficient levels of vitamin D in a new study from Emory University School of Medicine.
Just a numbers game? Making sense of health statistics
Presidential candidates use them to persuade voters, drug companies use them to sell their products, and the media spin them in all kinds of ways, but nobody - candidates, reporters, let alone health consumers - understands them. Health statistics fill today's information environment, but even most doctors, who must make daily decisions and recommendations based on numerical data - for instance, to calculate the risks of a certain drug or surgical intervention, or to inform a patient of the possible benefits versus harms of cancer screening - lack the basic statistical literacy they require to make such decisions effectively.
Oral vitamin D may help prevent some skin infections
A study led by researchers at the University of California, San Diego School of Medicine suggests that use of oral Vitamin D supplements bolsters production of a protective chemical normally found in the skin, and may help prevent skin infections that are a common result of atopic dermatitis, the most common form of eczema.
Endoscopy may not be necessary in asymptomatic children after caustic ingestion
A new study from researchers in Italy reports that endoscopy may not be necessary in children who show no symptoms after a caustic ingestion. The results demonstrated that the incidence of severe abnormalities of the esophagus in children without any early symptoms is very low and an endoscopy could be avoided. The study appears in the September issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE).
Study takes a closer look at safety gaps during patient 'sign out'
Patients may receive poor or delayed care after sign-out—the transfer of a patient from one doctor to another during a shift change—Yale School of Medicine researchers report in an Archives of Internal Medicine study.
Exhaled nitric oxide monitoring does not improve on guidelines-based asthma management
Exhaled nitric oxide serves as a biomarker of inflammation in the lungs, and proponents have suggested that monitoring nitric oxide levels could help improve management of asthma. However, new research, which will be published in the Sept. 20 issue of The Lancet, indicates that adolescent and young adult patients whose asthma is managed according to the latest NIH guidelines do not benefit from the addition of nitric-oxide monitoring.
New data on melanoma treatment
People who carry a particular genetic variant are at significantly increased risk of developing malignant melanoma, new research shows.

News discussion:

Medicine & Health news